John Dundon | Medicine and Dentistry | Research Excellence Award

Dr. John Dundon | Medicine and Dentistry | Research Excellence Award 

Orthopedic Research Institute of New Jersey | United States

Dr. John M. Dundon is a board-certified orthopedic surgeon and clinician–scientist with a distinguished research profile focused on adult reconstruction, total hip and knee arthroplasty, surgical innovation, and value-based orthopedic care. As a Full Partner at Tri-County Orthopedics and previously at the Orthopedic Institute of New Jersey, Dr. Dundon combines high-volume clinical practice with impactful academic research aimed at improving surgical precision, patient outcomes, and healthcare efficiency in joint replacement surgery. A central theme of Dr. Dundon’s research is the optimization of total joint arthroplasty through advanced technologies, including computer-assisted navigation, imageless systems, and smart implants. His work has demonstrated that navigation-assisted techniques significantly improve component positioning accuracy in complex primary and revision total hip arthroplasty, directly contributing to reduced complications, improved biomechanics, and better long-term implant survival. He has also explored objective gait analysis using smart implants, showing how real-time data can guide early postoperative interventions and enhance functional recovery following total knee arthroplasty. Dr. Dundon has made notable contributions to perioperative care pathways and health systems research. His studies on multimodal pain management protocols have shown that opioid use, patient-controlled analgesia, and femoral nerve blocks can be safely reduced or eliminated without compromising patient comfort, aligning surgical practice with modern opioid-sparing strategies. Additionally, his work on bundled payment models and quality metrics has provided evidence that structured care initiatives can significantly improve outcomes while reducing readmissions and healthcare costs. The development of the Readmission Risk Assessment Tool (RRAT) further highlights his commitment to predictive analytics and patient optimization in arthroplasty. His research portfolio also addresses implant biomechanics, tribocorrosion, femoral stem sizing, leg-length discrepancy correction, and postoperative imaging utilization, reflecting a comprehensive approach to both technical and clinical challenges in orthopedic surgery. Dr. Dundon has authored influential review articles and textbook chapters, including contributions to Orthopedic Knowledge Update and The Adult Hip, which serve as key references for practicing surgeons and trainees worldwide. With an extensive record of peer-reviewed publications, national and international presentations, and leadership roles within major orthopedic societies such as the American Academy of Orthopaedic Surgeons and the American Association of Hip and Knee Surgeons, Dr. Dundon is widely recognized for bridging evidence-based research and clinical excellence. His research profile reflects sustained innovation, interdisciplinary collaboration, and a clear commitment to advancing the safety, effectiveness, and value of modern joint replacement surgery.

Citation Metrics (Scopus)

1000
600
400
200
50
0

Citations
641

i10index
20

h-index
9

Citations

i10-index

h-index

View Scopus Profile

Featured Publications

Carlos Escobar | Medicine and Dentistry | Best Researcher Award- 25576

Prof. Dr. Carlos Escobar | Medicine and Dentistry | Best Researcher Award

Prof. Dr. Carlos Escobar | Hospital La Paz, Madrid | Spain

Dr. Carlos Escobar Cervantes is a leading cardiologist and researcher based in Madrid, Spain. With over two decades of experience in cardiovascular medicine, he has held esteemed roles in top Spanish hospitals, contributed prolifically to scientific literature, and has played leadership roles within major cardiology societies. He currently serves as Facultativo Adjunto del Servicio de Cardiología at Hospital Universitario La Paz and is the Scientific Director of the Consorcio DTX, focusing on digital therapeutics (DTx) and AI in health. His work bridges clinical expertise and digital innovation, making him a pioneer in the integration of artificial intelligence in cardiovascular care. Dr. Escobar’s dedication extends beyond patient care—he is also a respected academic and educator, shaping future medical professionals. His contribution to cardiovascular pharmacology, hypertension, ischemic heart disease, and public health through clinical trials, publications, and professional society work makes him an exemplary candidate for international recognition.

Profile

Scopus

Education

Dr. Carlos Escobar Cervantes earned his Medical Degree in Medicine and Surgery from the Universidad Autónoma de Madrid (1993–1999). He pursued academic excellence and scientific inquiry further by completing a PhD in Medicine at the Universidad de Alcalá in 2007, where he was awarded the prestigious distinction of Sobresaliente Cum Laude, by unanimous decision of the examining board. This rigorous academic path provided him with a strong foundation for his career in internal medicine, clinical cardiology, and scientific research. Additionally, his commitment to academic growth is reflected in his successful qualification as a Profesor Ayudante Doctor recognized by ANECA in June 2011. Further enriching his academic and leadership portfolio, Dr. Escobar completed the Leadership Development Program in Public Healthcare Organizations from ESADE Business School (2011–2012), one of Spain’s most prestigious business institutions. His education uniquely combines clinical, scientific, and managerial expertise—vital for innovative cardiovascular leadership.

Professional Experience

Dr. Escobar Cervantes has held successive and prestigious roles in cardiology across some of Madrid’s foremost healthcare institutions. He began his career as a Médico Adjunto de Cardiología at Hospital Universitario Ramón y Cajal (2006–2008), then transitioned to Hospital Universitario Infanta Sofía (2008–2012), and has been serving at Hospital Universitario La Paz since 2012. Currently, he also coordinates outpatient cardiology services and care continuity at La Paz, a role he took on in June 2023, showcasing his capacity for healthcare system organization and innovation. Since December 2023, Dr. Escobar has been the Scientific Director of the Consorcio DTX, focused on the application of digital health tools, including AI, in cardiology. He is also the Co-founder of Samira DTX, emphasizing his proactive stance in developing evidence-based digital therapeutic solutions. His career represents a seamless integration of bedside excellence, scientific leadership, and organizational impact in Spanish and international cardiology.

Research Interests

Dr. Escobar’s research focuses on ischemic heart disease, arterial hypertension, atrial fibrillation, and pulmonary thromboembolism. As both principal investigator and co-investigator, he has played key roles in clinical trials exploring innovative therapies in these domains. In recent years, he has expanded his research to encompass digital therapeutics (DTx) and the application of artificial intelligence (AI) in cardiovascular medicine. He is an active contributor to the Sociedad Española de Cardiología (SEC) and the European Society of Cardiology, where he is a member of the cardiovascular pharmacology and hypertension working groups. His research is deeply translational—bringing bench-side developments to bedside application. His commitment to improving cardiovascular care outcomes through technological innovation, patient-centered care models, and robust clinical investigation underscores his status as a forward-thinking leader in cardiovascular science. Dr. Escobar’s dual commitment to both scientific discovery and clinical impact has made him a valued voice in the cardiology research community.

Awards and Professional Recognition

Dr. Carlos Escobar is a highly respected figure in cardiology, having served as President of the Clinical Cardiology Section of the Sociedad Española de Cardiología (SEC). He has been a member of the SEC’s Research Agency and is an active contributor to several working groups under both SEC and the European Society of Cardiology (ESC). His academic and research contributions have earned him memberships in international editorial boards such as the World Journal of Hypertension, ISRN Nephrology, and the Journal of Cardiology and Therapeutics. His peer-review activity includes esteemed journals like Annals of Internal Medicine, Diabetes Care, and the Journal of Hypertension, reflecting his reputation as an authority in cardiovascular science. These honors reflect a career distinguished not only by scientific productivity but also by community trust and professional excellence. His leadership, publications, and collaborative spirit make him a worthy nominee for high-level international awards.

Publications

Cost-utility analysis of dapagliflozin for the treatment of symptomatic chronic heart failure in Spain

The gut microbiota and its role in the development of cardiovascular disease

Management of children with heterozygous familial hypercholesterolaemia worldwide: a meta-analysis

Artificial intelligence: a promising tool for the clinical cardiologist

Magnitude of chronic kidney disease in Spain

Conclusion

Dr. Carlos Escobar Cervantes exemplifies the union of clinical excellence, academic integrity, and technological foresight. His contributions to cardiology span groundbreaking clinical research, digital health innovation, and transformative educational leadership. His work has directly improved cardiovascular care standards in Spain and beyond, earning him recognition across editorial boards, societies, and digital medicine consortia. Dr. Escobar is not only a scientific leader but also an innovator, teacher, and strategist, positioning him as a well-rounded and future-focused candidate for any top-tier international medical or scientific award. His pioneering initiatives in AI-driven cardiovascular therapeutics, combined with his extensive academic publications and clinical leadership, embody the spirit of 21st-century medical excellence. He is therefore highly recommended for recognition in awards celebrating innovation, excellence, and translational impact in cardiovascular medicine.